IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Jonathan W. Ayers sold 1,000 shares of the business’s stock in a transaction on Thursday, February 18th. The stock was sold at an average price of $555.56, for a total transaction of $555,560.00. Following the completion of the sale, the director now directly owns 652,737 shares in the company, valued at approximately $362,634,567.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ IDXX opened at $536.91 on Tuesday. The firm has a market capitalization of $45.87 billion, a P/E ratio of 93.54, a price-to-earnings-growth ratio of 4.55 and a beta of 0.88. The company has a current ratio of 1.65, a quick ratio of 1.24 and a debt-to-equity ratio of 1.93. The firm’s fifty day moving average price is $504.77 and its two-hundred day moving average price is $443.23. IDEXX Laboratories, Inc. has a 1 year low of $168.65 and a 1 year high of $573.99.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, February 2nd. The company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.62. The company had revenue of $720.90 million for the quarter, compared to analyst estimates of $680.03 million. IDEXX Laboratories had a net margin of 19.20% and a return on equity of 198.91%. IDEXX Laboratories’s revenue for the quarter was up 19.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.04 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 6.13 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in IDEXX Laboratories by 57.1% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 15,278 shares of the company’s stock valued at $7,637,000 after purchasing an additional 5,554 shares during the last quarter. Camden Capital LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $360,000. Park Avenue Securities LLC boosted its holdings in shares of IDEXX Laboratories by 27.0% during the 4th quarter. Park Avenue Securities LLC now owns 3,450 shares of the company’s stock worth $1,725,000 after buying an additional 733 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its stake in IDEXX Laboratories by 7.7% in the 3rd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 14,730 shares of the company’s stock valued at $5,791,000 after buying an additional 1,056 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in IDEXX Laboratories by 76.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 20,290 shares of the company’s stock valued at $10,142,000 after buying an additional 8,763 shares during the last quarter. Institutional investors own 85.06% of the company’s stock.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Read More: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.